229 related articles for article (PubMed ID: 24634417)
1. Protein kinase d as a potential chemotherapeutic target for colorectal cancer.
Wei N; Chu E; Wipf P; Schmitz JC
Mol Cancer Ther; 2014 May; 13(5):1130-41. PubMed ID: 24634417
[TBL] [Abstract][Full Text] [Related]
2. A novel small-molecule inhibitor of protein kinase D blocks pancreatic cancer growth in vitro and in vivo.
Harikumar KB; Kunnumakkara AB; Ochi N; Tong Z; Deorukhkar A; Sung B; Kelland L; Jamieson S; Sutherland R; Raynham T; Charles M; Bagherzadeh A; Foxton C; Boakes A; Farooq M; Maru D; Diagaradjane P; Matsuo Y; Sinnett-Smith J; Gelovani J; Krishnan S; Aggarwal BB; Rozengurt E; Ireson CR; Guha S
Mol Cancer Ther; 2010 May; 9(5):1136-46. PubMed ID: 20442301
[TBL] [Abstract][Full Text] [Related]
3. Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.
Li QQ; Hsu I; Sanford T; Railkar R; Balaji N; Sourbier C; Vocke C; Balaji KC; Agarwal PK
Cell Mol Life Sci; 2018 Mar; 75(5):939-963. PubMed ID: 29071385
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of protein kinase D suppresses epithelial ovarian cancer via MAPK/ERK1/2/Runx2 signalling axis.
Tyagi K; Roy A; Mandal S
Cell Signal; 2023 Oct; 110():110849. PubMed ID: 37562720
[TBL] [Abstract][Full Text] [Related]
5. SD-208, a novel protein kinase D inhibitor, blocks prostate cancer cell proliferation and tumor growth in vivo by inducing G2/M cell cycle arrest.
Tandon M; Salamoun JM; Carder EJ; Farber E; Xu S; Deng F; Tang H; Wipf P; Wang QJ
PLoS One; 2015; 10(3):e0119346. PubMed ID: 25747583
[TBL] [Abstract][Full Text] [Related]
6. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
Flanigan SA; Pitts TM; Eckhardt SG; Tentler JJ; Tan AC; Thorburn A; Leong S
Clin Cancer Res; 2010 Nov; 16(22):5436-46. PubMed ID: 20943761
[TBL] [Abstract][Full Text] [Related]
7. MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.
García-García C; Rivas MA; Ibrahim YH; Calvo MT; Gris-Oliver A; Rodríguez O; Grueso J; Antón P; Guzmán M; Aura C; Nuciforo P; Jessen K; Argilés G; Dienstmann R; Bertotti A; Trusolino L; Matito J; Vivancos A; Chicote I; Palmer HG; Tabernero J; Scaltriti M; Baselga J; Serra V
Clin Cancer Res; 2015 Dec; 21(24):5499-5510. PubMed ID: 26272063
[TBL] [Abstract][Full Text] [Related]
8. New pyrazolopyrimidine inhibitors of protein kinase d as potent anticancer agents for prostate cancer cells.
Tandon M; Johnson J; Li Z; Xu S; Wipf P; Wang QJ
PLoS One; 2013; 8(9):e75601. PubMed ID: 24086585
[TBL] [Abstract][Full Text] [Related]
9. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
[TBL] [Abstract][Full Text] [Related]
10. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.
Capasso A; Pitts TM; Klauck PJ; Bagby SM; Westbrook L; Kaplan J; Soleimani M; Spreafico A; Tentler JJ; Diamond JR; Arcaroli JJ; Messersmith WA; Eckhardt SG; Leong S
Anticancer Drugs; 2018 Oct; 29(9):827-838. PubMed ID: 30048249
[TBL] [Abstract][Full Text] [Related]
11. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
[TBL] [Abstract][Full Text] [Related]
12. Opposing growth regulatory roles of protein kinase D isoforms in human keratinocytes.
Ryvkin V; Rashel M; Gaddapara T; Ghazizadeh S
J Biol Chem; 2015 Apr; 290(17):11199-208. PubMed ID: 25802335
[TBL] [Abstract][Full Text] [Related]
13. Developments in the Discovery and Design of Protein Kinase D Inhibitors.
Gilles P; Voets L; Van Lint J; De Borggraeve WM
ChemMedChem; 2021 Jul; 16(14):2158-2171. PubMed ID: 33829655
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
15. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
Liu YC; Tsai JJ; Weng YS; Hsu FT
Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
[TBL] [Abstract][Full Text] [Related]
16. Protein kinases D2 and D3 are novel growth regulators in HCC1806 triple-negative breast cancer cells.
Hao Q; McKenzie R; Gan H; Tang H
Anticancer Res; 2013 Feb; 33(2):393-9. PubMed ID: 23393329
[TBL] [Abstract][Full Text] [Related]
17. The synthesized 2-(2-fluorophenyl)-6,7-methylenedioxyquinolin-4-one (CHM-1) promoted G2/M arrest through inhibition of CDK1 and induced apoptosis through the mitochondrial-dependent pathway in CT-26 murine colorectal adenocarcinoma cells.
Chou LC; Yang JS; Huang LJ; Wu HC; Lu CC; Chiang JH; Chen KT; Kuo SC; Chung JG
J Gastroenterol; 2009; 44(10):1055-63. PubMed ID: 19688288
[TBL] [Abstract][Full Text] [Related]
18. Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model.
Ding C; Li L; Yang T; Fan X; Wu G
BMC Cancer; 2016 Oct; 16(1):791. PubMed ID: 27729020
[TBL] [Abstract][Full Text] [Related]
19. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
20. Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.
Borges S; Perez EA; Thompson EA; Radisky DC; Geiger XJ; Storz P
Mol Cancer Ther; 2015 Jun; 14(6):1306-16. PubMed ID: 25852060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
